Serum Institute has struck a partnership with Dynavax and Aurobindo Pharma with US-based company COVAXX for new vaccine candidates while Bharat Biotech has tied up with Ocugen to explore marketing of its existing contender, Covaxin, in the US.
Adding more arrows to their quivers in the battle against COVID-19, two Indian companies are developing a new vaccine with partners in the US while a third is attempting to expand its reach in the country.
Serum Institute of India Pvt. Ltd. announced on 23 December a tie up with Dynavax Technologies Corporation, a commercial stage biopharmaceutical company developing and commercializing novel vaccines
CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.
As CEO Anderson backs high prices for innovative drugs in Europe
Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.
